Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jun 20, 2016 5:48pm
108 Views
Post# 24981556

RE:RE:Zenith Update Perspectives

RE:RE:Zenith Update PerspectivesBDAZ, I always very much appreciate your objectivity and remarkable scientific insight. You guide a steady ship and keep us on course.

I've become somewhat too emotional in my responses and I should probably wait a week or 2 after Don presents and read other perspectives before I post.

My father was a large animal veternarian and while acedemically I studied mathematics I also studied biology for 3 years in university. I appreciate science and the wonderful complexities of living cells and species. And so I have a very crude empathy for the complexity of biochemistry and the difficulty of trials. A good friend of my son has a degree in biology and a masters in bio-engineering. He couldn't find work so he did his clinical trials certification. He explained to me the complexity of managing quality control in trials, the imprecise and difficult challenges in recruiting and other challenges. So I guess I should appreciate that zen3694 is in dosing and that there might be some hints by Q4 2016.

I guess my business discipline kicks in when I hear Don present and I expect professionalism.

That being said, I am very much long on the science and over the years this is largely due to reading your explanations of how these compounds work and the incredible post hoc analysis since June 2013.

GLTA
Toinv
Bullboard Posts